[
  {
    "source_document": "2024-06-25_00:00:00.000_Progress_Notes_91596",
    "kappa_flc": "0.08 mg/dL",
    "lambda_flc": "<0.15 mg/dL",
    "kappa_lambda_ratio": ">0.57",
    "date_of_lab": "2024-06-25",
    "evidence_sentences": [
      "1/16/24: KFLC 242.66, LFLC <0.15, kappa/lambda ratio >1733.29.",
      "1/24/24: KFLC 203.94, LFLC <0.15, ratio >1456.71.",
      "MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.",
      "Myeloma markers on 10/8/2019 had all improved: M spike 0.3 g/dL, KFLC 1.34 mg/dL, LFLC 0.92 mg/dL, K/L 1.46.",
      "Result Value Ref Range Kappa Free Light Chain 0.08 (L) 0.76 - 6.83 mg/dL Lambda Free Light Chain <0.15 (L) 0.68 - 4.58 mg/dL Kappa/Lambda FLC Ratio >0.57 (L) 0.66 - 2.22"
    ],
    "context": "{\"kappa_flc\": \"0.08 mg/dL\", \"lambda_flc\": \"<0.15 mg/dL\", \"kappa_lambda_ratio\": \">0.57\", \"date_of_lab\": \"2024-06-25\", \"evidence_sentences\": [\"1/16/24: KFLC 242.66, LFLC <0.15, kappa/lambda ratio >1733.29.\", \"1/24/24: KFLC 203.94, LFLC <0.15, ratio >1456.71.\", \"MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.\", \"Myeloma markers on 10/8/2019 had all improved: M spike 0.3 g/dL, KFLC 1.34 mg/dL, LFLC 0.92 mg/dL, K/L 1.46.\", \"Result Value Ref Range Kappa Free Light Chain 0.08 (L) 0.76 - 6.83 mg/dL Lambda Free Light Chain <0.15 (L) 0.68 - 4.58 mg/dL Kappa/Lambda FLC Ratio >0.57 (L) 0.66 - 2.22\"]}"
  },
  {
    "source_document": "2024-04-17_00:00:00.000_Progress_Notes_91591",
    "kappa_flc": "129.54 mg/dL",
    "lambda_flc": "15 mg/dL",
    "kappa_lambda_ratio": ">914.29",
    "date_of_lab": "2023-11-28",
    "evidence_sentences": [
      "MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.",
      "11/28/23: kappa free light chain (KFLC) 129.54mg /dL, lambda free light chain (LFLC) 15mg /dL, kappa/lambda ratio >914.29."
    ],
    "context": "{\"kappa_flc\": \"129.54 mg/dL\", \"lambda_flc\": \"15 mg/dL\", \"kappa_lambda_ratio\": \">914.29\", \"date_of_lab\": \"2023-11-28\", \"evidence_sentences\": [\"MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.\", \"11/28/23: kappa free light chain (KFLC) 129.54mg /dL, lambda free light chain (LFLC) 15mg /dL, kappa/lambda ratio >914.29.\"]}"
  },
  {
    "source_document": "2024-02-08_00:00:00.000_Progress_Notes_91427",
    "kappa_flc": "16.18 mg/dL",
    "lambda_flc": "<0.15 mg/dL",
    "kappa_lambda_ratio": ">115.57",
    "date_of_lab": "2024-02-22",
    "evidence_sentences": [
      "Baseline free light chains (per notes): Kappa 65, Lambda 0.34, Kappa/Lambda 190",
      "Pre-CAR T evaluation: MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57.",
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.",
      "2/22/24: KFLC 16.18, LFLC <0.15, kappa/lambda ratio >115.57."
    ],
    "context": "{\"kappa_flc\": \"16.18 mg/dL\", \"lambda_flc\": \"<0.15 mg/dL\", \"kappa_lambda_ratio\": \">115.57\", \"date_of_lab\": \"2024-02-22\", \"evidence_sentences\": [\"Baseline free light chains (per notes): Kappa 65, Lambda 0.34, Kappa/Lambda 190\", \"Pre-CAR T evaluation: MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57.\", \"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\", \"2/22/24: KFLC 16.18, LFLC <0.15, kappa/lambda ratio >115.57.\"]}"
  },
  {
    "source_document": "2024-04-17_00:00:00.000_IMTX_Conference_Note_91586",
    "kappa_flc": "203.94 mg/dL",
    "lambda_flc": "<0.15 mg/dL",
    "kappa_lambda_ratio": ">1456.71",
    "date_of_lab": "2024-02-08",
    "evidence_sentences": [
      "On 02/22/24, KFLC were 16.18; LFLC <0.15; FLC ratio >115.57.",
      "in 2019 was 6 g/dL with kappa free light chains of 65 mg/dL.",
      "Latest Reference Range & Units 04/08/24 07:15 Kappa Free Light Chain 0.76 - 6.83 mg/dL <9.81 (L) Lambda Free Light Chain 0.68 - 4.58 mg/dL <1.91 (L) Kappa/Lambda FLC Ratio 0.66 - 2.22 Unable to calculate.",
      "Kappa Free Light Chain 203.94 (H) 0.76 - 6.83 mg/dL Lambda Free Light Chain <0.15 (L) 0.68 - 4.58 mg/dL Kappa/Lambda FLC Ratio >1456.71 (H) 0.66 - 2.22",
      "light chains to 42.66, ratio > 1733.29, 2 and spikes on SPEP = 2.8 IgG kappa, kappa monoclonal free light chain too small to quantify, IgG 3393 (1/24/24)"
    ],
    "context": "{\"kappa_flc\": \"203.94 mg/dL\", \"lambda_flc\": \"<0.15 mg/dL\", \"kappa_lambda_ratio\": \">1456.71\", \"date_of_lab\": \"2024-02-08\", \"evidence_sentences\": [\"On 02/22/24, KFLC were 16.18; LFLC <0.15; FLC ratio >115.57.\", \"in 2019 was 6 g/dL with kappa free light chains of 65 mg/dL.\", \"Latest Reference Range & Units 04/08/24 07:15 Kappa Free Light Chain 0.76 - 6.83 mg/dL <9.81 (L) Lambda Free Light Chain 0.68 - 4.58 mg/dL <1.91 (L) Kappa/Lambda FLC Ratio 0.66 - 2.22 Unable to calculate.\", \"Kappa Free Light Chain 203.94 (H) 0.76 - 6.83 mg/dL Lambda Free Light Chain <0.15 (L) 0.68 - 4.58 mg/dL Kappa/Lambda FLC Ratio >1456.71 (H) 0.66 - 2.22\", \"light chains to 42.66, ratio > 1733.29, 2 and spikes on SPEP = 2.8 IgG kappa, kappa monoclonal free light chain too small to quantify, IgG 3393 (1/24/24)\"]}"
  },
  {
    "source_document": "2024-03-05_00:00:00.000_IMTX_Conference_Note_91479",
    "kappa_flc": "56.21 mg/dL",
    "lambda_flc": "<3.08 mg/dL",
    "kappa_lambda_ratio": ">115.57",
    "date_of_lab": "2024-02-22",
    "evidence_sentences": [
      "Latest Reference Range & Units 02/22/24 09:20 Kappa Free Light Chain 0.76 - 6.83 mg/dL 56.21 (H) Lambda Free Light Chain 0.68 - 4.58 mg/dL <3.08 (L) Kappa/Lambda FLC Ratio 0.66 - 2.22 >115.57 (H)"
    ],
    "context": "{\"kappa_flc\": \"56.21 mg/dL\", \"lambda_flc\": \"<3.08 mg/dL\", \"kappa_lambda_ratio\": \">115.57\", \"date_of_lab\": \"2024-02-22\", \"evidence_sentences\": [\"Latest Reference Range & Units 02/22/24 09:20 Kappa Free Light Chain 0.76 - 6.83 mg/dL 56.21 (H) Lambda Free Light Chain 0.68 - 4.58 mg/dL <3.08 (L) Kappa/Lambda FLC Ratio 0.66 - 2.22 >115.57 (H)\"]}"
  },
  {
    "source_document": "2021-12-27_00:00:00.000_Progress_Notes_91111",
    "kappa_flc": "64.9 mg/dL",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2019-03-XX",
    "evidence_sentences": [
      "Labs 12/15 show M-spike 0.1, KFLC 1.24, K/L ratio 1.72.",
      "Diagnoses in 3/2019. M-spike of 6, calcium of 9.7, an IgG of 5610, kappa FLC 64.9, kappa/lambda ratio of 190, total protein 10.7, UPEP was positive by immunofixation, and bone marrow showed myeloma.",
      "SPEP on 12/20/2021 showed M-spike of 0.1. Free light chains: kappa free light chain was 1.24 and kappa/lambda ratio was 1.72."
    ],
    "context": "{\"kappa_flc\": \"64.9 mg/dL\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2019-03-XX\", \"evidence_sentences\": [\"Labs 12/15 show M-spike 0.1, KFLC 1.24, K/L ratio 1.72.\", \"Diagnoses in 3/2019. M-spike of 6, calcium of 9.7, an IgG of 5610, kappa FLC 64.9, kappa/lambda ratio of 190, total protein 10.7, UPEP was positive by immunofixation, and bone marrow showed myeloma.\", \"SPEP on 12/20/2021 showed M-spike of 0.1. Free light chains: kappa free light chain was 1.24 and kappa/lambda ratio was 1.72.\"]}"
  },
  {
    "source_document": "2023-11-27_00:00:00.000_Progress_Notes_91273",
    "kappa_flc": "65 mg/dL",
    "lambda_flc": "0.34 mg/dL",
    "kappa_lambda_ratio": ">1456.71",
    "date_of_lab": "2019-03-XX",
    "evidence_sentences": [
      "M spike at 6 g/dL, KFLC 65 mg/dL, LFLC 0.34 mg/dL, and K/L 190.88.",
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.",
      "MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57. IgG Kappa M spike 0.1",
      "In 6/2021, he had kappa FLC of 20.78, lambda FLC of 0.24, kappa/lambda ratio of 86.58.",
      "M-spike of 6, calcium of 9.7, an IgG of 5610, kappa FLC 64.9, kappa/lambda ratio of 190, total protein 10.7, UPEP was positive by immunofixation, and bone marrow showed myeloma."
    ],
    "context": "{\"kappa_flc\": \"65 mg/dL\", \"lambda_flc\": \"0.34 mg/dL\", \"kappa_lambda_ratio\": \">1456.71\", \"date_of_lab\": \"2019-03-XX\", \"evidence_sentences\": [\"M spike at 6 g/dL, KFLC 65 mg/dL, LFLC 0.34 mg/dL, and K/L 190.88.\", \"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\", \"MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57. IgG Kappa M spike 0.1\", \"In 6/2021, he had kappa FLC of 20.78, lambda FLC of 0.24, kappa/lambda ratio of 86.58.\", \"M-spike of 6, calcium of 9.7, an IgG of 5610, kappa FLC 64.9, kappa/lambda ratio of 190, total protein 10.7, UPEP was positive by immunofixation, and bone marrow showed myeloma.\"]}"
  },
  {
    "source_document": "2021-12-23_00:00:00.000_Progress_Notes_91107",
    "kappa_flc": "",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2021-06-XX",
    "evidence_sentences": [
      "In 6/2021, he had kappa FLC of 20.78, lambda FLC"
    ],
    "context": "{\"kappa_flc\": \"\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2021-06-XX\", \"evidence_sentences\": [\"In 6/2021, he had kappa FLC of 20.78, lambda FLC\"]}"
  },
  {
    "source_document": "2024-01-22_00:00:00.000_Progress_Notes_91317",
    "kappa_flc": "242 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">1733.29",
    "date_of_lab": "2021-12-27",
    "evidence_sentences": [
      "MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.",
      "FLC of 20.78, lambda FLC of 0.24, kappa/lambda ratio of 86.58."
    ],
    "context": "{\"kappa_flc\": \"242 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">1733.29\", \"date_of_lab\": \"2021-12-27\", \"evidence_sentences\": [\"MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.\", \"FLC of 20.78, lambda FLC of 0.24, kappa/lambda ratio of 86.58.\"]}"
  },
  {
    "source_document": "2022-01-07_00:00:00.000_Progress_Notes_91124",
    "kappa_flc": "",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "",
    "evidence_sentences": [
      "His kappa was 1.24, lambda 0.72, kappa lambda 1.72."
    ],
    "context": "{\"kappa_flc\": \"\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"\", \"evidence_sentences\": [\"His kappa was 1.24, lambda 0.72, kappa lambda 1.72.\"]}"
  },
  {
    "source_document": "2024-02-06_00:00:00.000_Progress_Notes_91413",
    "kappa_flc": "204 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">1456.71",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.",
      "Myeloma labs 11/28/2023: KFLC 129.5 mg/dL, LFLC <0.15 mg/dL."
    ],
    "context": "{\"kappa_flc\": \"204 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">1456.71\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\", \"Myeloma labs 11/28/2023: KFLC 129.5 mg/dL, LFLC <0.15 mg/dL.\"]}"
  },
  {
    "source_document": "2024-02-10_00:00:00.000_Progress_Notes_91437",
    "kappa_flc": "204 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">1456.71",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"204 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">1456.71\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2022-02-22_00:00:00.000_Progress_Notes_91240",
    "kappa_flc": "64.9 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2021-XX-XX",
    "evidence_sentences": [
      "of 6,calcium of 9.7, an IgG of 5610,kappa FLC 64.9, kappa/lambda ratio of 190, total protein 10.7, UPEP was positiveby immunofixation,and bone marrow showed myeloma.",
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.",
      "In 10/2020, kappa FLC was 24.67, kappa/lambda ratio was 137.06."
    ],
    "context": "{\"kappa_flc\": \"64.9 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2021-XX-XX\", \"evidence_sentences\": [\"of 6,calcium of 9.7, an IgG of 5610,kappa FLC 64.9, kappa/lambda ratio of 190, total protein 10.7, UPEP was positiveby immunofixation,and bone marrow showed myeloma.\", \"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\", \"In 10/2020, kappa FLC was 24.67, kappa/lambda ratio was 137.06.\"]}"
  },
  {
    "source_document": "2024-03-11_00:00:00.000_H&P_91495",
    "kappa_flc": "20.78 mg/dL",
    "lambda_flc": "0.24 mg/dL",
    "kappa_lambda_ratio": ">1733.29",
    "date_of_lab": "2021-06-XX",
    "evidence_sentences": [
      "FLC ratio >1733.29",
      "MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57. IgG Kappa M spike 0.1.",
      "In 6/2021, he had kappa FLC of 20.78, lambda FLC of 0.24, kappa/lambda ratio of 86.58.",
      "Pre therapy 1/16/2024: Kappa free light chains to 42.66, ratio > 1733.29, 2 and spikes on SPEP = 2.8 IgG kappa, kappa monoclonal free light chain too small to quantify, IgG 3393 (1/24/24)",
      "M spike at initial diagnosis in 2019 was 6 g/dL with kappa free light chains of 65 mg/dL.",
      "MM markers (1/24): KFLC 204, LFLC <",
      "11/28/23: kappa free light chain (KFLC) 129.54mg /dL, lambda free light chain (LFLC) 15mg /dL, kappa/lambda ratio >914.29. SPEP with IgG kappa monoclonal component, M-spike 2.0g/dL; kappa monoclonal free light chain, M-spike too small"
    ],
    "context": "{\"kappa_flc\": \"20.78 mg/dL\", \"lambda_flc\": \"0.24 mg/dL\", \"kappa_lambda_ratio\": \">1733.29\", \"date_of_lab\": \"2021-06-XX\", \"evidence_sentences\": [\"FLC ratio >1733.29\", \"MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57. IgG Kappa M spike 0.1.\", \"In 6/2021, he had kappa FLC of 20.78, lambda FLC of 0.24, kappa/lambda ratio of 86.58.\", \"Pre therapy 1/16/2024: Kappa free light chains to 42.66, ratio > 1733.29, 2 and spikes on SPEP = 2.8 IgG kappa, kappa monoclonal free light chain too small to quantify, IgG 3393 (1/24/24)\", \"M spike at initial diagnosis in 2019 was 6 g/dL with kappa free light chains of 65 mg/dL.\", \"MM markers (1/24): KFLC 204, LFLC <\", \"11/28/23: kappa free light chain (KFLC) 129.54mg /dL, lambda free light chain (LFLC) 15mg /dL, kappa/lambda ratio >914.29. SPEP with IgG kappa monoclonal component, M-spike 2.0g/dL; kappa monoclonal free light chain, M-spike too small\"]}"
  },
  {
    "source_document": "2024-01-31_00:00:00.000_Progress_Notes_91377",
    "kappa_flc": "129.5 mg/dL",
    "lambda_flc": "<0.15 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2023-11-28",
    "evidence_sentences": [
      "Myeloma labs 11/28/2023: KFLC 129.5 mg/dL, LFLC <0.15 mg/dL. M-spike 2.0 IgG kappa and TSTQ kappa light chain.",
      "In 6/2021, he had kappa FLC of 20.78, lambda FLC of 0.24, kappa/lambda ratio of 86.58."
    ],
    "context": "{\"kappa_flc\": \"129.5 mg/dL\", \"lambda_flc\": \"<0.15 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2023-11-28\", \"evidence_sentences\": [\"Myeloma labs 11/28/2023: KFLC 129.5 mg/dL, LFLC <0.15 mg/dL. M-spike 2.0 IgG kappa and TSTQ kappa light chain.\", \"In 6/2021, he had kappa FLC of 20.78, lambda FLC of 0.24, kappa/lambda ratio of 86.58.\"]}"
  },
  {
    "source_document": "2024-02-02_00:00:00.000_Progress_Notes_91387",
    "kappa_flc": "65 mg/dL",
    "lambda_flc": "0.34 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2019-XX-XX",
    "evidence_sentences": [
      "Baseline free light chains (per notes): Kappa 65, Lambda 0.34, Kappa/Lambda 190"
    ],
    "context": "{\"kappa_flc\": \"65 mg/dL\", \"lambda_flc\": \"0.34 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2019-XX-XX\", \"evidence_sentences\": [\"Baseline free light chains (per notes): Kappa 65, Lambda 0.34, Kappa/Lambda 190\"]}"
  },
  {
    "source_document": "2022-01-10_00:00:00.000_Progress_Notes_91134",
    "kappa_flc": "64.9 mg/dL",
    "lambda_flc": "<0.15 mg/dL",
    "kappa_lambda_ratio": ">1733.29",
    "date_of_lab": "2019-XX-XX",
    "evidence_sentences": [
      "an IgG of 5610,kappa FLC 64.9, kappa/lambda ratio of 190, total protein 10.7, UPEP was positiveby immunofixation,and bone marrow showed myeloma.",
      "MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"64.9 mg/dL\", \"lambda_flc\": \"<0.15 mg/dL\", \"kappa_lambda_ratio\": \">1733.29\", \"date_of_lab\": \"2019-XX-XX\", \"evidence_sentences\": [\"an IgG of 5610,kappa FLC 64.9, kappa/lambda ratio of 190, total protein 10.7, UPEP was positiveby immunofixation,and bone marrow showed myeloma.\", \"MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2023-12-01_00:00:00.000_Progress_Notes_91285",
    "kappa_flc": "<0.06 mg/dL",
    "lambda_flc": "<1.61 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-04-08",
    "evidence_sentences": [
      "Labs from 4/8/2024: Kappa <0.06 mg/dL, Lambda <1.61 mg/dL."
    ],
    "context": "{\"kappa_flc\": \"<0.06 mg/dL\", \"lambda_flc\": \"<1.61 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-04-08\", \"evidence_sentences\": [\"Labs from 4/8/2024: Kappa <0.06 mg/dL, Lambda <1.61 mg/dL.\"]}"
  },
  {
    "source_document": "2024-04-23_00:00:00.000_Progress_Notes_91592",
    "kappa_flc": "65 mg/dL",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2019-XX-XX",
    "evidence_sentences": [
      "Baseline free light chains (per notes): Kappa 65, Lambda 0.34, Kappa/Lambda 190"
    ],
    "context": "{\"kappa_flc\": \"65 mg/dL\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2019-XX-XX\", \"evidence_sentences\": [\"Baseline free light chains (per notes): Kappa 65, Lambda 0.34, Kappa/Lambda 190\"]}"
  },
  {
    "source_document": "2024-02-07_00:00:00.000_Progress_Notes_91425",
    "kappa_flc": "204 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">1456.71",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"204 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">1456.71\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2024-02-03_00:00:00.000_Consults_91400",
    "kappa_flc": "16.18 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": "> 115.57",
    "date_of_lab": "2024-02-22",
    "evidence_sentences": [
      "MM labs (2/22): KFLC  16.18, LFLC < 0.15, ratio > 115.57. IgG Kappa M spike 0.1."
    ],
    "context": "{\"kappa_flc\": \"16.18 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \"> 115.57\", \"date_of_lab\": \"2024-02-22\", \"evidence_sentences\": [\"MM labs (2/22): KFLC  16.18, LFLC < 0.15, ratio > 115.57. IgG Kappa M spike 0.1.\"]}"
  },
  {
    "source_document": "2024-04-01_00:00:00.000_Progress_Notes_91568",
    "kappa_flc": "4.48 mg/dL",
    "lambda_flc": "0.7 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2021-09-01",
    "evidence_sentences": [
      "On 09/01/21  Serum  kappa was down to 4.48 with a lambda 0.7, kappa lambda of 6.31."
    ],
    "context": "{\"kappa_flc\": \"4.48 mg/dL\", \"lambda_flc\": \"0.7 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2021-09-01\", \"evidence_sentences\": [\"On 09/01/21  Serum  kappa was down to 4.48 with a lambda 0.7, kappa lambda of 6.31.\"]}"
  },
  {
    "source_document": "2022-01-18_00:00:00.000_BMT_Conference_Note_91158",
    "kappa_flc": "20.78 mg/dL",
    "lambda_flc": "0.24 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2021-06-21",
    "evidence_sentences": [
      "Of note, on 06/21 his kappa had been 20.78 per dL, lambda 0.24 and a kappa lambda of  86.58."
    ],
    "context": "{\"kappa_flc\": \"20.78 mg/dL\", \"lambda_flc\": \"0.24 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2021-06-21\", \"evidence_sentences\": [\"Of note, on 06/21 his kappa had been 20.78 per dL, lambda 0.24 and a kappa lambda of  86.58.\"]}"
  },
  {
    "source_document": "2022-07-13_00:00:00.000_Telephone_Encounter_91256",
    "kappa_flc": "42.66 mg/dL",
    "lambda_flc": "",
    "kappa_lambda_ratio": "> 1733.29",
    "date_of_lab": "2024-01-16",
    "evidence_sentences": [
      "Pre therapy 1/16/2024: Kappa free light chains to 42.66, ratio > 1733.29, 2 and spikes on SPEP = 2.8 IgG kappa, kappa monoclonal free light chain too small to quantify, IgG 3393 (1/24/24)"
    ],
    "context": "{\"kappa_flc\": \"42.66 mg/dL\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"> 1733.29\", \"date_of_lab\": \"2024-01-16\", \"evidence_sentences\": [\"Pre therapy 1/16/2024: Kappa free light chains to 42.66, ratio > 1733.29, 2 and spikes on SPEP = 2.8 IgG kappa, kappa monoclonal free light chain too small to quantify, IgG 3393 (1/24/24)\"]}"
  },
  {
    "source_document": "2021-11-13_00:00:00.000_Consults_91085",
    "kappa_flc": "64.9 mg/dL",
    "lambda_flc": "0.34 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2019-XX-XX",
    "evidence_sentences": [
      "In 12/2020 kappa was 30.75, kappa lambda 16184.",
      "At diagnosis, he had a calcium of 9.7, an IgG of 5610, kappa lambda ratio of 190, total protein 10.7, albumin of 2.3. UPEP was positive by immunofixation. Vitamin D of 10, kappa was 64.9, lambda 0.34, and his bone marrow showed myeloma."
    ],
    "context": "{\"kappa_flc\": \"64.9 mg/dL\", \"lambda_flc\": \"0.34 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2019-XX-XX\", \"evidence_sentences\": [\"In 12/2020 kappa was 30.75, kappa lambda 16184.\", \"At diagnosis, he had a calcium of 9.7, an IgG of 5610, kappa lambda ratio of 190, total protein 10.7, albumin of 2.3. UPEP was positive by immunofixation. Vitamin D of 10, kappa was 64.9, lambda 0.34, and his bone marrow showed myeloma.\"]}"
  },
  {
    "source_document": "2024-02-03_00:00:00.000_Progress_Notes_91395",
    "kappa_flc": "1.24 mg/dL",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2021-12-15",
    "evidence_sentences": [
      "Labs 12/15 show M-spike 0.1, KFLC 1.24, K/L ratio 1.72."
    ],
    "context": "{\"kappa_flc\": \"1.24 mg/dL\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2021-12-15\", \"evidence_sentences\": [\"Labs 12/15 show M-spike 0.1, KFLC 1.24, K/L ratio 1.72.\"]}"
  },
  {
    "source_document": "2024-03-14_00:00:00.000_Progress_Notes_91512",
    "kappa_flc": "65 mg/dL",
    "lambda_flc": "0.34 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "XXXX-XX-XX",
    "evidence_sentences": [
      "Baseline free light chains (per notes): Kappa 65, Lambda 0.34, Kappa/Lambda 190",
      "baseline labs showing an IgG kappa monoclonal protein of 6 g/dL, with kappa light chain of 65, lambda of 0.34 and ratio of 190."
    ],
    "context": "{\"kappa_flc\": \"65 mg/dL\", \"lambda_flc\": \"0.34 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"XXXX-XX-XX\", \"evidence_sentences\": [\"Baseline free light chains (per notes): Kappa 65, Lambda 0.34, Kappa/Lambda 190\", \"baseline labs showing an IgG kappa monoclonal protein of 6 g/dL, with kappa light chain of 65, lambda of 0.34 and ratio of 190.\"]}"
  },
  {
    "source_document": "2021-12-15_00:00:00.000_Progress_Notes_91091",
    "kappa_flc": "30.75 mg/dL",
    "lambda_flc": "0.73 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2020-12-XX",
    "evidence_sentences": [
      "His most recent labs on 12/1/21 show an M-spike of 0.2, kappa FLC 1.45, lambda FLC 0.73, and kappa/lambda ratio of 1.99.",
      "In 12/2020, kappa FLC was 30.75, kappa/lambda ratio 161.84."
    ],
    "context": "{\"kappa_flc\": \"30.75 mg/dL\", \"lambda_flc\": \"0.73 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2020-12-XX\", \"evidence_sentences\": [\"His most recent labs on 12/1/21 show an M-spike of 0.2, kappa FLC 1.45, lambda FLC 0.73, and kappa/lambda ratio of 1.99.\", \"In 12/2020, kappa FLC was 30.75, kappa/lambda ratio 161.84.\"]}"
  },
  {
    "source_document": "2024-03-24_00:00:00.000_Progress_Notes_91557",
    "kappa_flc": "20.78 mg/dL",
    "lambda_flc": "0.24 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2021-06-XX",
    "evidence_sentences": [
      "In 6/2021, he had kappa FLC of 20.78, lambda FLC of 0.24, kappa/lambda ratio of 86.58."
    ],
    "context": "{\"kappa_flc\": \"20.78 mg/dL\", \"lambda_flc\": \"0.24 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2021-06-XX\", \"evidence_sentences\": [\"In 6/2021, he had kappa FLC of 20.78, lambda FLC of 0.24, kappa/lambda ratio of 86.58.\"]}"
  },
  {
    "source_document": "2024-02-01_00:00:00.000_Progress_Notes_91383",
    "kappa_flc": "204 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">1456.71",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"204 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">1456.71\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2022-01-07_00:00:00.000_Progress_Notes_91121",
    "kappa_flc": "204 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">1456.71",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"204 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">1456.71\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2024-01-24_00:00:00.000_H&P_91325",
    "kappa_flc": "1.24 mg/dL",
    "lambda_flc": "0.72 mg/dL",
    "kappa_lambda_ratio": ">1733.29",
    "date_of_lab": "2021-12-15",
    "evidence_sentences": [
      "MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.",
      "12/15: SPEP IgG kappa M spike of 0.1, Kappa light chain 1.24, lambda light chain 0.72. Kappa/ lambda ratio 1.72, beta 2 microglobulin 1.3"
    ],
    "context": "{\"kappa_flc\": \"1.24 mg/dL\", \"lambda_flc\": \"0.72 mg/dL\", \"kappa_lambda_ratio\": \">1733.29\", \"date_of_lab\": \"2021-12-15\", \"evidence_sentences\": [\"MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.\", \"12/15: SPEP IgG kappa M spike of 0.1, Kappa light chain 1.24, lambda light chain 0.72. Kappa/ lambda ratio 1.72, beta 2 microglobulin 1.3\"]}"
  },
  {
    "source_document": "2024-03-10_00:00:00.000_Progress_Notes_91489",
    "kappa_flc": "242 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">1733.29",
    "date_of_lab": "2024-01-16",
    "evidence_sentences": [
      "MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"242 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">1733.29\", \"date_of_lab\": \"2024-01-16\", \"evidence_sentences\": [\"MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2021-12-17_00:00:00.000_Progress_Notes_91098",
    "kappa_flc": "64.9 mg/dL",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2019-03-XX",
    "evidence_sentences": [
      "At diagnosis M-spike was 6, Hgb 8.4, calcium of 9.7, albumin 2.3, adjusted calcium level 11.1, creatinine 0.99. IgG of 5610, kappa FLC 64.9, lappa/lambda ratio of 190, total protein 10.7."
    ],
    "context": "{\"kappa_flc\": \"64.9 mg/dL\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2019-03-XX\", \"evidence_sentences\": [\"At diagnosis M-spike was 6, Hgb 8.4, calcium of 9.7, albumin 2.3, adjusted calcium level 11.1, creatinine 0.99. IgG of 5610, kappa FLC 64.9, lappa/lambda ratio of 190, total protein 10.7.\"]}"
  },
  {
    "source_document": "2024-03-06_00:00:00.000_Progress_Notes_91482",
    "kappa_flc": "242 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">1733.29",
    "date_of_lab": "2024-01-16",
    "evidence_sentences": [
      "MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"242 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">1733.29\", \"date_of_lab\": \"2024-01-16\", \"evidence_sentences\": [\"MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2024-02-13_00:00:00.000_Progress_Notes_91443",
    "kappa_flc": "42.66 mg/dL",
    "lambda_flc": "",
    "kappa_lambda_ratio": ">1733.29",
    "date_of_lab": "2024-01-16",
    "evidence_sentences": [
      "Pre therapy 1/16/2024: Kappa free light chains to 42.66, ratio > 1733.29, 2 and spikes on SPEP = 2.8 IgG kappa, kappa monoclonal free light chain too small to quantify, IgG 3393 (1/24/24)"
    ],
    "context": "{\"kappa_flc\": \"42.66 mg/dL\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \">1733.29\", \"date_of_lab\": \"2024-01-16\", \"evidence_sentences\": [\"Pre therapy 1/16/2024: Kappa free light chains to 42.66, ratio > 1733.29, 2 and spikes on SPEP = 2.8 IgG kappa, kappa monoclonal free light chain too small to quantify, IgG 3393 (1/24/24)\"]}"
  },
  {
    "source_document": "2024-03-13_00:00:00.000_Nursing_Note_91505",
    "kappa_flc": "242 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">1733.29",
    "date_of_lab": "2024-01-16",
    "evidence_sentences": [
      "MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"242 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">1733.29\", \"date_of_lab\": \"2024-01-16\", \"evidence_sentences\": [\"MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2024-03-13_00:00:00.000_Nursing_Note_91506",
    "kappa_flc": "16.18 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">115.57",
    "date_of_lab": "2024-02-22",
    "evidence_sentences": [
      "MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57."
    ],
    "context": "{\"kappa_flc\": \"16.18 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">115.57\", \"date_of_lab\": \"2024-02-22\", \"evidence_sentences\": [\"MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57.\"]}"
  },
  {
    "source_document": "2024-01-17_00:00:00.000_Progress_Notes_91306",
    "kappa_flc": "1.24 mg/dL",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2021-12-15",
    "evidence_sentences": [
      "Labs 12/15 show M-spike 0.1, KFLC 1.24, K/L ratio 1.72. Bone marrow 12/17 is negative by flow."
    ],
    "context": "{\"kappa_flc\": \"1.24 mg/dL\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2021-12-15\", \"evidence_sentences\": [\"Labs 12/15 show M-spike 0.1, KFLC 1.24, K/L ratio 1.72. Bone marrow 12/17 is negative by flow.\"]}"
  },
  {
    "source_document": "2024-01-31_00:00:00.000_Consults_91374",
    "kappa_flc": "65 mg/dL",
    "lambda_flc": "0.34 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2019-03-24",
    "evidence_sentences": [
      "Myeloma markers on 3/24/2019 included an SPEP which showed an IgG kappa M spike at 6 g/dL, KFLC 65 mg/dL, LFLC 0.34 mg/dL, and K/L 190.88."
    ],
    "context": "{\"kappa_flc\": \"65 mg/dL\", \"lambda_flc\": \"0.34 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2019-03-24\", \"evidence_sentences\": [\"Myeloma markers on 3/24/2019 included an SPEP which showed an IgG kappa M spike at 6 g/dL, KFLC 65 mg/dL, LFLC 0.34 mg/dL, and K/L 190.88.\"]}"
  },
  {
    "source_document": "2024-01-26_00:00:00.000_Consults_91337",
    "kappa_flc": "",
    "lambda_flc": "",
    "kappa_lambda_ratio": ">1733.29",
    "date_of_lab": "2024-01-16",
    "evidence_sentences": [
      "MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \">1733.29\", \"date_of_lab\": \"2024-01-16\", \"evidence_sentences\": [\"MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2024-02-22_00:00:00.000_Progress_Notes_91459",
    "kappa_flc": "<0.06 mg/dL",
    "lambda_flc": "<1.61 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-04-08",
    "evidence_sentences": [
      "Labs from 4/8/2024: Kappa <0.06 mg/dL, Lambda <1.61 mg/dL, SPEP with M-spike 0.3 g/dL, IgG kappa"
    ],
    "context": "{\"kappa_flc\": \"<0.06 mg/dL\", \"lambda_flc\": \"<1.61 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-04-08\", \"evidence_sentences\": [\"Labs from 4/8/2024: Kappa <0.06 mg/dL, Lambda <1.61 mg/dL, SPEP with M-spike 0.3 g/dL, IgG kappa\"]}"
  },
  {
    "source_document": "2024-03-13_00:00:00.000_Progress_Notes_91509",
    "kappa_flc": "42.66 mg/dL",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-01-16",
    "evidence_sentences": [
      "Pre therapy 1/16/2024: Kappa free light chains to 42.66, ratio > 1733.29, 2 and spikes on SPEP = 2.8 IgG kappa, kappa monoclonal free light chain too small to quantify, IgG 3393 (1/24/24)"
    ],
    "context": "{\"kappa_flc\": \"42.66 mg/dL\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-01-16\", \"evidence_sentences\": [\"Pre therapy 1/16/2024: Kappa free light chains to 42.66, ratio > 1733.29, 2 and spikes on SPEP = 2.8 IgG kappa, kappa monoclonal free light chain too small to quantify, IgG 3393 (1/24/24)\"]}"
  },
  {
    "source_document": "2024-02-05_00:00:00.000_Progress_Notes_91406",
    "kappa_flc": "204 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"204 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2024-01-29_00:00:00.000_Progress_Notes_91357",
    "kappa_flc": "242 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-01-16",
    "evidence_sentences": [
      "S/p bridging isatuximab/carfilzomib/dex with no response >> Talequetamab C1 (1/24-2/16/24) with M spike 2.8-->1, KFLC 42.6-->16.18",
      "MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"242 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-01-16\", \"evidence_sentences\": [\"S/p bridging isatuximab/carfilzomib/dex with no response >> Talequetamab C1 (1/24-2/16/24) with M spike 2.8-->1, KFLC 42.6-->16.18\", \"MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2024-01-27_00:00:00.000_Consults_91344",
    "kappa_flc": "204 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"204 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2023-07-18_00:00:00.000_Procedure_Nursing_Note_91267",
    "kappa_flc": "204 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">1456.71",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"204 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">1456.71\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2024-01-18_00:00:00.000_Progress_Notes_91309",
    "kappa_flc": "242 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">1733.29",
    "date_of_lab": "2024-01-16",
    "evidence_sentences": [
      "MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.",
      "Pre-CAR T evaluation: MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57. IgG Kappa M spike 0.1"
    ],
    "context": "{\"kappa_flc\": \"242 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">1733.29\", \"date_of_lab\": \"2024-01-16\", \"evidence_sentences\": [\"MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.\", \"Pre-CAR T evaluation: MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57. IgG Kappa M spike 0.1\"]}"
  },
  {
    "source_document": "2022-01-19_00:00:00.000_Progress_Notes_91165",
    "kappa_flc": "",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2020-10-XX",
    "evidence_sentences": [
      "In 10/2020 kappa was 24.67, kappa lambda 137.06."
    ],
    "context": "{\"kappa_flc\": \"\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2020-10-XX\", \"evidence_sentences\": [\"In 10/2020 kappa was 24.67, kappa lambda 137.06.\"]}"
  },
  {
    "source_document": "2024-02-20_00:00:00.000_Procedure_Nursing_Note_91454",
    "kappa_flc": "",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "Talequetamab C1 (1/24-2/16/24) with M spike 2.8-->1, KFLC 42.6-->16.18"
    ],
    "context": "{\"kappa_flc\": \"\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"Talequetamab C1 (1/24-2/16/24) with M spike 2.8-->1, KFLC 42.6-->16.18\"]}"
  },
  {
    "source_document": "2024-01-17_00:00:00.000_Progress_Notes_91305",
    "kappa_flc": "",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-02-16",
    "evidence_sentences": [
      "Talequetamab C1 (1/24-2/16/24) with M spike 2.8-->1, KFLC 42.6-->16.18"
    ],
    "context": "{\"kappa_flc\": \"\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-02-16\", \"evidence_sentences\": [\"Talequetamab C1 (1/24-2/16/24) with M spike 2.8-->1, KFLC 42.6-->16.18\"]}"
  },
  {
    "source_document": "2023-12-07_00:00:00.000_Progress_Notes_91298",
    "kappa_flc": "",
    "lambda_flc": "",
    "kappa_lambda_ratio": ">1456.71",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \">1456.71\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2024-03-16_00:00:00.000_Progress_Notes_91518",
    "kappa_flc": "16.18 mg/dL",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-02-XX",
    "evidence_sentences": [
      "S/p bridging isatuximab/carfilzomib/dex with no response >> Talequetamab C1 (1/24-2/16/24) with M spike 2.8-->1, KFLC 42.6-->16.18"
    ],
    "context": "{\"kappa_flc\": \"16.18 mg/dL\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-02-XX\", \"evidence_sentences\": [\"S/p bridging isatuximab/carfilzomib/dex with no response >> Talequetamab C1 (1/24-2/16/24) with M spike 2.8-->1, KFLC 42.6-->16.18\"]}"
  },
  {
    "source_document": "2024-01-24_00:00:00.000_Progress_Notes_91323",
    "kappa_flc": "16.18 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": "> 115.57",
    "date_of_lab": "2024-02-22",
    "evidence_sentences": [
      "MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57."
    ],
    "context": "{\"kappa_flc\": \"16.18 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \"> 115.57\", \"date_of_lab\": \"2024-02-22\", \"evidence_sentences\": [\"MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57.\"]}"
  },
  {
    "source_document": "2024-03-25_00:00:00.000_Progress_Notes_91561",
    "kappa_flc": "16.18 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": "> 115.57",
    "date_of_lab": "2024-02-22",
    "evidence_sentences": [
      "Pre-CAR T evaluation: MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57."
    ],
    "context": "{\"kappa_flc\": \"16.18 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \"> 115.57\", \"date_of_lab\": \"2024-02-22\", \"evidence_sentences\": [\"Pre-CAR T evaluation: MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57.\"]}"
  },
  {
    "source_document": "2024-04-08_00:00:00.000_Progress_Notes_91576",
    "kappa_flc": "204 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": ">1456.71",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa."
    ],
    "context": "{\"kappa_flc\": \"204 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \">1456.71\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa.\"]}"
  },
  {
    "source_document": "2024-03-22_00:00:00.000_Progress_Notes_91548",
    "kappa_flc": "1.24 mg/dL",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2021-12-15",
    "evidence_sentences": [
      "Labs 12/15 show M-spike 0.1, KFLC 1.24, K/L ratio 1.72."
    ],
    "context": "{\"kappa_flc\": \"1.24 mg/dL\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2021-12-15\", \"evidence_sentences\": [\"Labs 12/15 show M-spike 0.1, KFLC 1.24, K/L ratio 1.72.\"]}"
  },
  {
    "source_document": "2022-01-30_00:00:00.000_Progress_Notes_91197",
    "kappa_flc": "242 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2023-01-16",
    "evidence_sentences": [
      "MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"242 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2023-01-16\", \"evidence_sentences\": [\"MM markers (1/16): KFLC 242, LFLC < 0.15, ratio >1733.29, M spike 2.8 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2022-01-11_00:00:00.000_Progress_Notes_91138",
    "kappa_flc": "16.18 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-02-22",
    "evidence_sentences": [
      "Pre-CAR T evaluation: MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57. IgG Kappa M spike 0.1."
    ],
    "context": "{\"kappa_flc\": \"16.18 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-02-22\", \"evidence_sentences\": [\"Pre-CAR T evaluation: MM labs (2/22): KFLC 16.18, LFLC < 0.15, ratio > 115.57. IgG Kappa M spike 0.1.\"]}"
  },
  {
    "source_document": "2022-02-22_00:00:00.000_Progress_Notes_91238",
    "kappa_flc": "204 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ."
    ],
    "context": "{\"kappa_flc\": \"204 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG kappa, Kappa free light chain TSTQ.\"]}"
  },
  {
    "source_document": "2024-01-30_00:00:00.000_Progress_Notes_91369",
    "kappa_flc": "204 mg/dL",
    "lambda_flc": "< 0.15 mg/dL",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG"
    ],
    "context": "{\"kappa_flc\": \"204 mg/dL\", \"lambda_flc\": \"< 0.15 mg/dL\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"MM markers (1/24): KFLC 204, LFLC < 0.15, ratio >1456.71, M spike 2.6 IgG\"]}"
  },
  {
    "source_document": "2024-03-20_00:00:00.000_Progress_Notes_91537",
    "kappa_flc": "42.6 mg/dL",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-01-24",
    "evidence_sentences": [
      "S/p bridging isatuximab/carfilzomib/dex with no response >> Talequetamab C1 (1/24-2/16/24) with M spike 2.8-->1, KFLC 42.6-->16.18"
    ],
    "context": "{\"kappa_flc\": \"42.6 mg/dL\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-01-24\", \"evidence_sentences\": [\"S/p bridging isatuximab/carfilzomib/dex with no response >> Talequetamab C1 (1/24-2/16/24) with M spike 2.8-->1, KFLC 42.6-->16.18\"]}"
  },
  {
    "source_document": "2022-02-02_00:00:00.000_Progress_Notes_91205",
    "kappa_flc": "16.18 mg/dL",
    "lambda_flc": "",
    "kappa_lambda_ratio": "",
    "date_of_lab": "2024-02-16",
    "evidence_sentences": [
      "S/p bridging isatuximab/carfilzomib/dex with no response >> Talequetamab C1 (1/24-2/16/24) with M spike 2.8-->1, KFLC 42.6-->16.18"
    ],
    "context": "{\"kappa_flc\": \"16.18 mg/dL\", \"lambda_flc\": \"\", \"kappa_lambda_ratio\": \"\", \"date_of_lab\": \"2024-02-16\", \"evidence_sentences\": [\"S/p bridging isatuximab/carfilzomib/dex with no response >> Talequetamab C1 (1/24-2/16/24) with M spike 2.8-->1, KFLC 42.6-->16.18\"]}"
  }
]